How institutions capture and correct themselves
Why did medical bodies, universities and media adopt the affirmative model, and how do some reverse course?
The “affirmative model” is not one single protocol. In its broadest form, it means treating a person’s stated gender identity as valid, opposing attempts to change that identity, and seeking to reduce distress and barriers to social or medical transition. In clinical settings, it can range from respectful listening and practical support to social transition, puberty suppression, cross-sex hormones and surgery.

Key facts
2015 In 2015, the American Psychological Association adopted guidelines promoting transgender-affirmative psychological practice.
2018 In 2018, the American Academy of Pediatrics endorsed a “gender-affirmative care model”; it reaffirmed that policy in August 2023.
2022 WPATH published Standards of Care Version 8 in 2022, replacing its 2012 Version 7 guidance.
2020 Finland’s COHERE issued a 2020 recommendation placing psychosocial support at the centre of care for most minors.
2022 Sweden’s National Board of Health and Welfare advised restraint on hormonal treatment for under-18s in February 2022.
2024 The Cass Review published its final report on 10 April 2024 after examining England’s paediatric gender services.
2024 NHS England stopped routine prescribing of puberty-suppressing hormones for gender dysphoria in under-18s on 12 March 2024.
Background
The “affirmative model” is not one single protocol. In its broadest form, it means treating a person’s stated gender identity as valid, opposing attempts to change that identity, and seeking to reduce distress and barriers to social or medical transition. In clinical settings, it can range from respectful listening and practical support to social transition, puberty suppression, cross-sex hormones and surgery.
Medical bodies, universities and media organisations did not all make the same decisions, at the same time, or for the same reasons. It is therefore inaccurate to say that every institution was “captured” in a literal or centrally directed sense. What can be documented is a rapid convergence of professional language, training, policy statements and reporting norms from the mid-2010s onwards.
This convergence occurred in a context of genuine concern. Trans-identifying people have reported discrimination, family rejection, bullying and difficulties obtaining healthcare. Professional organisations sought to correct historical mistreatment, including coercive attempts to alter sexual orientation or gender expression. The American Psychological Association’s 2015 guidelines framed transgender-affirmative practice as a response to stigma, barriers to care and clinicians’ limited familiarity with this patient group (APA, 2015).
By 2018, the American Academy of Pediatrics had recommended comprehensive, developmentally appropriate gender-affirming healthcare, professional education, family support and advocacy against discrimination (AAP, 2018). WPATH’s Standards of Care, especially Version 8 in 2022, became influential internationally as a professional reference point. Universities incorporated similar frameworks into teaching, equality policies, student services and research language. Newsrooms increasingly adopted style guidance that prioritised a person’s self-declared name and pronouns.
What the documents say
Affirmation was presented as an ethical response to stigma
The APA guidelines were explicitly practice guidelines rather than binding clinical rules. They urged psychologists to understand the effects of stigma and discrimination, avoid assumptions, and provide competent, developmentally appropriate care. The AAP policy likewise argued that discrimination damages children’s wellbeing and that paediatricians should support gender-diverse young people and their families (APA, 2015; AAP, 2018).
These documents mattered beyond their formal scope. A policy statement from a large professional association can shape curricula, continuing professional development, institutional risk assessments and public messaging. Once an approach is described as inclusive, evidence-based and protective of a vulnerable group, dissent may be interpreted not as a dispute about evidence or thresholds for intervention, but as hostility towards patients.
The evidence reviews exposed a different problem
England’s later review process focused on a narrower question: what evidence supports particular medical interventions for children and adolescents with gender incongruence or dysphoria? NHS England commissioned evidence reviews from NICE in 2020. The Cass Review, led by Dr Hilary Cass, subsequently found major weaknesses in the evidence base, including a lack of robust long-term data on outcomes from puberty suppression and masculinising or feminising hormones in young people (Cass Review, 2024).
The Cass Review did not recommend abandoning care for distressed children. It called for a holistic assessment of mental health, neurodevelopment, family context, sexuality, safeguarding and co-existing conditions. It also recommended a research programme, better data collection and a more cautious approach to medical intervention. NHS England responded by ending routine commissioning of puberty-suppressing hormones for this indication in March 2024 and by building regional services intended to replace the former national Tavistock model (NHS England, 2024).
Other European health authorities had already moved in a more cautious direction. Finland’s Council for Choices in Health Care recommended psychosocial support as the first-line approach for minors in 2020, with puberty suppression considered case by case after careful assessment. Sweden’s National Board of Health and Welfare concluded in February 2022 that the risks of hormonal interventions for under-18s were likely to outweigh the possible benefits except in exceptional cases (COHERE Finland, 2020; Socialstyrelsen, 2022).
Law and regulation can accelerate correction
The courts and regulators have also affected institutional practice. In Bell v Tavistock, the High Court issued a declaration in December 2020 concerning the information a child would need to understand in order to consent to puberty blockers. The Court of Appeal overturned that declaration on 17 September 2021, holding that questions of consent should be determined by clinicians and courts in individual cases rather than by a general judicial declaration. The case nevertheless brought informed consent, uncertainty and treatment pathways into public view (Court of Appeal, 2021).
In the United Kingdom, the policy shift became regulatory as well as clinical. Following the Cass Review and advice from the Commission on Human Medicines, restrictions on the private sale and supply of puberty blockers for gender dysphoria or gender incongruence in under-18s were made indefinite from 1 January 2025. The Government stated that the order would be reviewed in 2027 (Department of Health and Social Care, 2024).
The positions
Supporters of the affirmative model argue that it responds humanely to a population exposed to stigma and elevated mental-health risks. They contend that delaying or obstructing care can intensify distress, and that clinicians should not impose scepticism as a test that patients must pass. They also argue that evidence in this field is difficult to generate because randomised trials may be impractical or ethically contested, and that absence of perfect evidence is not evidence of no benefit.
Critics, including gender-critical clinicians, parents and former patients, reply that empathy does not remove the ordinary duties of medicine: differential diagnosis, careful assessment of comorbidities, valid informed consent and strong evidence before interventions with potentially lasting effects. They argue that “affirmation” can become a default assumption which discourages exploration of autism, trauma, same-sex attraction, depression, anxiety, eating disorders, family difficulties or social influence.
A third position accepts the need for respectful, non-stigmatising care while rejecting both automatic affirmation and blanket refusal. This approach is increasingly visible in the Cass Review and Nordic guidance: support the child, investigate the whole clinical picture, avoid ideological assumptions, and reserve medical intervention for carefully assessed cases within a transparent evidence framework.
Interpretation
Beyond Gender’s reading is that institutional capture is usually less dramatic than conspiracy language suggests. It occurs when a moral premise becomes professionally mandatory before the empirical questions have been properly resolved. In this case, the premise was that questioning a declared gender identity risked harm, while affirmation represented safety and compassion.
That premise travelled efficiently through institutions. Advocacy language entered professional guidance; professional guidance entered university teaching and human-resources policy; those norms influenced journalists’ assumptions about what counted as respectful reporting. Each institution could then point to the others as evidence of consensus. This is a form of circular authority: policy is mistaken for proof, and agreement among organisations is mistaken for high-quality outcome data.
Correction begins when institutions separate values from evidence. Respect for gender-nonconforming people is a moral and civic obligation. It does not settle clinical questions about diagnosis, prognosis, consent, risks, benefits or the appropriate age for irreversible treatment. The Cass Review’s significance lies partly in restoring that distinction: compassionate care and rigorous evidence are not opposites.
Self-correction also requires mechanisms that are often uncomfortable for institutions: independent review, publication of evidence methods, open disagreement, outcome registries, external scrutiny and willingness to revise guidance. Institutions are most vulnerable to error when reputational risk makes staff fear asking ordinary professional questions.
Open questions
Important questions remain unresolved. Which young people, if any, are most likely to benefit from puberty suppression or cross-sex hormones? What are the long-term effects on fertility, sexual function, bone health, psychological development and desistance or detransition? How should clinicians distinguish persistent dysphoria from distress arising from other conditions or circumstances?
There are also institutional questions. Can professional associations revise guidance without treating earlier caution as prejudice? Can universities teach competing interpretations of sex, gender and medicine without punishing staff or students? Can media organisations report both discrimination against trans people and uncertainty about paediatric medicalisation without framing one concern as a denial of the other?
The most credible correction will not be a new orthodoxy. It will be a durable culture of evidence, clinical humility, safeguarding and free inquiry, in which the welfare of children takes priority over institutional reputation or political allegiance.
Sources
On the timeline
1 January 2015
The American Psychological Association adopted guidelines promoting transgender-affirmative psychological practice
In 2015, the American Psychological Association adopted guidelines promoting transgender-affirmative psychological practice.
1 January 2018
The American Academy of Pediatrics endorsed a “gender-affirmative care model”; it reaffirmed that policy in August 2023
In 2018, the American Academy of Pediatrics endorsed a “gender-affirmative care model”; it reaffirmed that policy in August 2023.
1 January 2020
Finland’s COHERE issued a 2020 recommendation placing psychosocial support at the centre of care for most minors
Finland’s COHERE issued a 2020 recommendation placing psychosocial support at the centre of care for most minors.
1 January 2022
WPATH published Standards of Care Version 8 in 2022, replacing its 2012 Version 7 guidance
WPATH published Standards of Care Version 8 in 2022, replacing its 2012 Version 7 guidance.
1 February 2022
Sweden’s National Board of Health and Welfare advised restraint on hormonal treatment for under-18s in February 2022
Sweden’s National Board of Health and Welfare advised restraint on hormonal treatment for under-18s in February 2022.
12 March 2024
NHS England stopped routine prescribing of puberty-suppressing hormones for gender dysphoria in under-18s on 12 March 20
NHS England stopped routine prescribing of puberty-suppressing hormones for gender dysphoria in under-18s on 12 March 2024.
10 April 2024
The Cass Review published its final report on 10 April 2024 after examining England’s paediatric gender services
The Cass Review published its final report on 10 April 2024 after examining England’s paediatric gender services.


